Select one or more newsletters to continue. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Management: Consider alternatives to this combination. Sinus node dysfunction may also be enhanced. Sotalol-induced bradycardia increases the risk of Torsade de Pointe, particularly following cardioversion. Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.Droperidol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Droperidol. 7.4 Insulin and Oral Antidiabetic Agents 7.5 Beta-2-Receptor Stimulants .
Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.These medications may interact and cause very harmful effects. Dose adjustments of agents that slow AV nodal conduction may be necessary when sotalol is initiated.• Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Management: Consider alternatives to this combination. Management: Consider alternatives to this combination.
Drugs A-Z Pill Identifier Supplements Symptom Checker … Drugs A-Z Pill Identifier Supplements Symptom Checker Diseases Dictionary Media I am followed by an EP both here in KY and in FL.
Consult drug interactions database for more detailed information.• Elderly: Bradycardia may be observed more frequently in elderly patients (>65 years of age); dosage reductions may be necessary.• Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine.
Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
Not all possible drug interactions are listed here. Does Sotalol Interact with other Medications? If QTc interval is ≥500 msec, reduce dose, prolong the dosing interval, or discontinue sotalol. If combined, monitor for QTc interval prolongation and ventricular arrhythmias.
QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Class III Antiarrhythmics (Highest Risk). Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Ceritinib: May enhance the bradycardic effect of Sotalol.
Monitor QTc interval periodically thereafter.IV: Measure QTc interval after completion of each infusion.Consult individual institutional policies and procedures.Beta-blockers, including sotalol, may cause erectile dysfunction.Adverse fetal/neonatal events have been reported with beta-blockers as a class. Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.
Use with caution in patients with compensated heart failure; monitor for a worsening of the condition and discontinue if symptoms of heart failure occur.
The risk associated with ophthalmic products is probably less than systemic products. Patients with additional risk factors for QTc prolongation may be at even higher risk.CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine. Epinephrine (Racemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of Epinephrine (Racemic). Sotalol/QT Prolonging Agents Interactions. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. The drug has an apparent volume of distribution of 1.2-2.4 liters/kg.